Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 5 publications
Intermittent treatment of BRAFV600E melanoma cells delays resistance by adaptive resensitization to drug rechallenge.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: March 15, 2022
Specificity of Phosphorylation Responses to Mitogen Activated Protein (MAP) Kinase Pathway Inhibitors in Melanoma Cells.
Journal: Molecular & cellular proteomics : MCP
Published: September 16, 2017
Erratum to: Large-Scale Examination of Factors Influencing Phosphopeptide Neutral Loss During Collision Induced Dissociation.
Journal: Journal of the American Society for Mass Spectrometry
Published: July 15, 2015
A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells.
Journal: Molecular & cellular proteomics : MCP
Published: December 04, 2014
Large-Scale Examination of Factors Influencing Phosphopeptide Neutral Loss during Collision Induced Dissociation.
Journal: Journal of the American Society for Mass Spectrometry
Published: December 01, 2014
Showing 1-5 of 5
Last Updated: 09/26/2026